Valsartan for heart failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Jan 2022: Trial registered, NCT05194111
  2. 11 Aug 2022: Trial started, NCT05194111

The trials

NCT05194111: Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

State
Under way
Phase
Phase 1 and Phase 2
People
70 planned
Started
11 Aug 2022
Primary completion
30 Nov 2028
Arms
Arm 2: Valsartan
Results
None posted
  1. 18 Jan 2022: Trial registered
  2. 11 Aug 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Copalia-hct component valsartan, Copalia component valsartan, Dafiro component valsartan, Dafiro-hct component valsartan, Diovan, Entresto component valsartan, Exforge component valsartan, Imprida component valsartan, Imprida-hct component valsartan, Prexxartan, Valturna component valsartan.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.